Hims & Hers Health (HIMS) Navigates Volatility Amid GLP-1 Speculation
Hims & Hers Health (HIMS) continues to captivate investors with its erratic stock performance, oscillating between $40 and $70 this year. The company's dual identity—as a potential pioneer in consumer health or a beneficiary of temporary GLP-1 drug hype—has fueled intense market debate.
Third-quarter results cut through the noise, revealing 49% revenue growth to $600 million and a 21% subscriber increase. While growth has moderated from earlier highs, the underlying business demonstrates remarkable resilience. Monthly online revenue per subscriber climbed 19% to $80, underscoring the platform's monetization strength.